

Bruker Corporation
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

(in millions)	June 30, 2016	December 31, 2015
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 232.5	\$ 267.1
Short-term investments	187.9	201.2
Accounts receivable, net	206.9	234.7
Inventories	471.0	422.0
Other current assets	117.1	106.5
Total current assets	1,215.4	1,231.5
Property, plant and equipment, net	236.8	231.1
Intangibles, net and other long-term assets	268.3	267.4
Total assets	<u>\$ 1,720.5</u>	<u>\$ 1,730.0</u>
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Current portion of long-term debt	\$ 20.3	\$ 0.6
Accounts payable	88.0	72.1
Customer advances	153.9	178.3
Other current liabilities	272.9	303.5
Total current liabilities	535.1	554.5
Long-term debt	322.7	265.2
Other long-term liabilities	192.3	177.4
Total shareholders' equity	670.4	732.9
Total liabilities and shareholders' equity	<u>\$ 1,720.5</u>	<u>\$ 1,730.0</u>

FOR FURTHER INFORMATION:

Stacey Desrochers, Treasurer & Director of Investor Relations
Tel: +1 (978) 663-3660, ext. 1115
Email: stacey.desrochers@bruker.com

Bruker Corporation
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

(in millions, except per share amounts)	Three Months Ended June 30,		Six Months Ended June 30,	
	2016	2015	2016	2015
Revenues	\$ 371.7	\$ 396.0	\$ 747.1	\$ 749.5
Cost of revenues	201.6	226.6	410.2	419.9
Gross profit	170.1	169.4	336.9	329.6
Operating expenses:				
Selling, general and administrative	100.9	98.5	193.6	193.1
Research and development	36.8	37.5	72.9	74.7
Other charges, net	12.0	1.8	16.0	15.0
Total operating expenses	149.7	137.8	282.5	282.8
Operating income	20.4	31.6	54.4	46.8
Interest and other income (expense), net	(2.6)	(6.2)	(8.2)	(9.7)
Income before income taxes and noncontrolling interest in consolidated subsidiaries	17.8	25.4	46.2	37.1
Income tax provision	3.0	2.3	7.8	7.1
Consolidated net income	14.8	23.1	38.4	30.0
Net income attributable to noncontrolling interests in consolidated subsidiaries	0.3	1.2	0.3	1.6
Net income attributable to Bruker Corporation	<u>\$ 14.5</u>	<u>\$ 21.9</u>	<u>\$ 38.1</u>	<u>\$ 28.4</u>
Net income per common share attributable to Bruker Corporation shareholders:				
Basic	<u>\$ 0.09</u>	<u>\$ 0.13</u>	<u>\$ 0.23</u>	<u>\$ 0.17</u>
Diluted	<u>\$ 0.09</u>	<u>\$ 0.13</u>	<u>\$ 0.23</u>	<u>\$ 0.17</u>
Weighted average common shares outstanding:				
Basic	<u>161.4</u>	<u>168.3</u>	<u>162.3</u>	<u>168.3</u>
Diluted	<u>162.4</u>	<u>169.7</u>	<u>163.3</u>	<u>169.7</u>

Bruker Corporation
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

(in millions)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2016	2015	2016	2015
Cash flows from operating activities:				
Consolidated net income	\$ 14.8	\$ 23.1	\$ 38.4	\$ 30.0
Adjustments to reconcile consolidated net income to cash flows				
from operating activities:				
Depreciation and amortization	13.5	13.2	26.7	26.7
Write-down of demonstration inventories to net realizable value	3.7	4.9	8.5	9.9
Stock-based compensation expense	2.1	1.4	4.3	3.6
Deferred income taxes	(1.3)	3.1	(4.0)	(0.6)
Loss (gain) on disposal of product line	-	0.2	-	0.2
Other non-cash expenses, net	7.3	(6.4)	9.0	0.9
Changes in operating assets and liabilities, net of acquisitions and divestitures:				
Accounts receivable	23.1	(8.9)	30.3	42.6
Inventories	(31.2)	(2.3)	(60.0)	(38.9)
Accounts payable and accrued expenses	(3.3)	(0.5)	(12.3)	(7.3)
Income taxes payable, net	(17.7)	(9.8)	(31.4)	(16.7)
Deferred revenue	(3.8)	2.0	5.4	(1.1)
Customer advances	12.0	(16.3)	(6.4)	(7.4)
Other changes in operating assets and liabilities, net	(1.1)	(5.2)	(4.4)	(16.4)
Net cash provided by (used in) operating activities	18.1	(1.5)	4.1	25.5
Cash flows from investing activities:				
Purchases of short-term investments	(11.4)	(27.6)	(33.1)	(49.1)
Maturities of short-term investments	28.4	18.8	50.1	40.3
Purchases of property, plant and equipment	(9.2)	(7.7)	(17.2)	(13.4)
Proceeds from sales of property, plant and equipment	0.3	0.7	0.9	0.7
Cash paid for acquisitions, net of cash acquired	(1.2)	-	(1.2)	-
Net cash provided by (used in) investing activities	6.9	(15.8)	(0.5)	(21.5)
Cash flows from financing activities:				
Proceeds from revolving lines of credit	41.0	10.0	77.0	10.0
Proceeds (repayment) of other debt, net	(0.2)	(0.1)	0.2	(0.2)
Proceeds from issuance of common stock, net	2.1	2.9	9.6	6.2
Payment of contingent consideration	-	(0.9)	-	(3.0)
Repurchase of common stock	(38.7)	(17.2)	(117.6)	(17.2)
Changes in restricted cash	0.8	0.6	0.7	1.4
Cash payments to noncontrolling interest	-	(0.5)	-	(0.5)
Payment of dividends	(6.5)	-	(13.0)	-
Excess tax benefit related to stock option awards	0.3	-	0.3	2.2
Net cash used in financing activities	(1.2)	(5.2)	(42.8)	(1.1)
Effect of exchange rate changes on cash and cash equivalents	(1.2)	8.8	4.6	(1.6)
Net change in cash and cash equivalents	22.6	(13.7)	(34.6)	1.3
Cash and cash equivalents at beginning of period	209.9	334.5	267.1	319.5
Cash and cash equivalents at end of period	\$ 232.5	\$ 320.8	\$ 232.5	\$ 320.8

Bruker Corporation
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES* (unaudited)

(in millions, except per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2016	2015	2016	2015
<i>Reconciliation of Non-GAAP Operating Income, Non-GAAP Profit Before Tax, Non-GAAP Net Income, and Non-GAAP EPS</i>				
GAAP Operating Income	\$ 20.4	\$ 31.6	\$ 54.4	\$ 46.8
Non-GAAP Adjustments:				
Restructuring Costs	3.7	5.2	7.5	8.5
Acquisition-Related Costs	8.1	(2.8)	10.0	(2.6)
Purchased Intangible Amortization	5.4	5.2	10.8	10.4
Other Costs	2.4	3.7	4.6	15.6
Total Non-GAAP Adjustments:	\$ 19.6	\$ 11.3	\$ 32.9	\$ 31.9
Non-GAAP Operating Income	\$ 40.0	\$ 42.9	\$ 87.3	\$ 78.7
Non-GAAP Operating Margin	10.8%	10.8%	11.7%	10.5%
Non-GAAP Interest & Other Income (Expense), net	(2.6)	(6.0)	(8.2)	(9.5)
Non-GAAP Profit Before Tax	37.4	36.9	79.1	69.2
Non-GAAP Income Tax Provision	(4.5)	(3.8)	(11.9)	(12.6)
Non-GAAP Tax Rate	12.0%	10.3%	15.0%	18.2%
Minority Interest	(0.3)	(1.2)	(0.3)	(1.6)
Non-GAAP Net Income Attributable to Bruker	32.6	31.9	66.9	55.0
Weighted Average Shares Outstanding (Diluted)	162.4	169.7	163.3	169.7
Non-GAAP Earnings Per Share	\$ 0.20	\$ 0.19	\$ 0.41	\$ 0.32

<i>Reconciliation of GAAP and Non-GAAP Gross Profit</i>				
GAAP Gross Profit	\$ 170.1	\$ 169.4	\$ 336.9	\$ 329.6
Non-GAAP Adjustments:				
Restructuring Costs	1.8	4.2	3.9	6.2
Acquisition-Related Costs	0.2	0.1	2.1	0.3
Purchased Intangible Amortization	4.7	4.7	9.3	9.4
Other Costs	0.1	-	0.1	-
Total Non-GAAP Adjustments:	6.8	9.0	15.4	15.9
Non-GAAP Gross Profit	\$ 176.9	\$ 178.4	\$ 352.3	\$ 345.5
Non-GAAP Gross Margin	47.6%	45.1%	47.2%	46.1%

<i>Reconciliation of GAAP and Non-GAAP Interest & Other Income (Expense), net</i>				
GAAP Interest & Other Income (Expense), net	\$ (2.6)	\$ (6.2)	\$ (8.2)	\$ (9.7)
Non-GAAP Adjustments:				
Sale of Product Line	-	0.2	-	0.2
Non-GAAP Interest & Other Income (Expense), net	\$ (2.6)	\$ (6.0)	\$ (8.2)	\$ (9.5)

<i>Reconciliation of GAAP Operating Cash Flow and Non-GAAP Free Cash Flow</i>				
GAAP Operating Cash Flow	\$ 18.1	\$ (1.5)	\$ 4.1	\$ 25.5
Non-GAAP Adjustments:				
Purchases of property, plant and equipment	(9.2)	(7.7)	(17.2)	(13.4)
Non-GAAP Free Cash Flow	\$ 8.9	\$ (9.2)	\$ (13.1)	\$ 12.1

<i>Reconciliation of GAAP Revenue and Non-GAAP Revenue</i>				
GAAP Revenue as of Prior Comparable Period	\$ 396.0	\$ 457.4	\$ 749.5	\$ 881.1
Non-GAAP Adjustments:				
Acquisitions and divestitures	12.0	(12.0)	17.2	(22.9)
Currency	-	(52.6)	(3.1)	(99.4)
Organic	(36.3)	3.2	(16.5)	(9.3)
Total Non-GAAP Adjustments:	(24.3)	(61.4)	(2.4)	(131.6)
Non-GAAP Revenue	\$ 371.7	\$ 396.0	\$ 747.1	\$ 749.5
Organic Revenue Growth	-9.2%	0.7%	-2.2%	-1.0%

* Please refer to our press release for a full explanation for the use of non-GAAP measures.